Trials / Unknown
UnknownNCT03495245
Identification of Potential Biomarkers for Pain
Development of a Serum Biomarker-Based Approach to Monitor Opioid Adherence and Minimize Substance Misuse in Chronic Pain Management
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Rowan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study investigates the potential of using serum biomarkers to assess pain in fibromyalgia patients.
Detailed description
At the heart of the opioid epidemic is the lack of an objective measure of pain, which will help evaluate the validity of the patients' perception that the current dosage of opioid is sufficient of insufficient to alleviate pain. This study will test the quantifiable proteins such as S100B and BDNF will serve as objective measures (biomarkers) of pain. Fibromyalgia patients will be recruited into two groups-- one that uses opioids and the other that does not. Blood will be collected every 6 months for two years. The serum will be used to assay for levels of S100B and BDNF, The pressure-pain threshold (PPT) data, as part of standard of care, will also be collected. Correlation will the be assessed.
Conditions
Timeline
- Start date
- 2018-03-28
- Primary completion
- 2020-09-30
- Completion
- 2021-09-30
- First posted
- 2018-04-11
- Last updated
- 2019-11-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03495245. Inclusion in this directory is not an endorsement.